Acorda R&D Day Explores Pipeline Opportunities
This article was originally published in The Pink Sheet Daily
Executive Summary
Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.
You may also be interested in...
Acorda Drops Epilepsy Candidate Once Central To Its Revenue Forecasts
Plumiaz, a nasal spray formulation of diazepam, is discontinued after it fails one of three Phase III trials undertaken to comply with 2014 FDA complete response letter.
Second Quarter Earnings Calls, In Brief
As second quarter earnings announcement shift into high gear, companies announce changes to manufacturing, progress on their drug launch efforts and their intentions to ramp up business development efforts.
Acorda Expands Pipeline With Neuronex And New Ampyra Indications
Acorda Therapeutics reports strong Ampyra results in the fourth quarter and highlights the other indications it’s pursuing for the drug, as well as the consumer marketing campaign the company is about to undertake. Acorda also announced its intention to acquire privately-held Neuronex Inc. for $2 million upfront plus $500,000 in R&D funding.